Tumid lupus is an uncommon variant of lupus erythematosus. Patients present with subcutaneous lesions. Ophthalmic literature reports disease manifestation as orbital inflammation. Autoimmune serology is often negative. Without a high index of suspicion, the diagnosis is easily overlooked delaying treatment. Tumid lupus is not significantly discussed in the Otolaryngologic literature. Here we present a Case Report of a male who initially presented to Ophthalmology with unilateral orbital complaint of eyelid puffiness. Orbital biopsy and subsequent biopsy of his submental skin lesions ultimately led to this unexpected diagnosis. We discuss the method to diagnose tumid lupus including representative histopathologic findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826658 | PMC |
| http://dx.doi.org/10.1016/j.amjoto.2017.01.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated autoimmunity in mice and humans.
J Exp Med
August 2024
Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.
Nucleic acid-sensing Toll-like receptors (TLR) 3, 7/8, and 9 are key innate immune sensors whose activities must be tightly regulated to prevent systemic autoimmune or autoinflammatory disease or virus-associated immunopathology. Here, we report a systematic scanning-alanine mutagenesis screen of all cytosolic and luminal residues of the TLR chaperone protein UNC93B1, which identified both negative and positive regulatory regions affecting TLR3, TLR7, and TLR9 responses. We subsequently identified two families harboring heterozygous coding mutations in UNC93B1, UNC93B1+/T93I and UNC93B1+/R336C, both in key negative regulatory regions identified in our screen.
View Article and Find Full Text PDFTumid lupus erythematosus in C1-inhibitor deficiency.
J R Coll Physicians Edinb
June 2024
Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust, Cottingham, UK.
A case of a 28-year-old woman with known C1-inhibitor deficiency (functional, Type II) with persistent bilateral non-pruritic, mildly photosensitive facial rash for 10 months following delivery of her second child is presented. Histology of the skin was suggestive of tumid lupus erythematosus (LE), but no other features of systemic LE (ANA, dsDNA negative) were evident. She had stopped danazol which was controlling the underlying disease, and once this was restarted and treatment for tumid lupus was started, she improved.
View Article and Find Full Text PDFTumid Lupus Erythematosus (TLE): A Review of a Rare Variant of Chronic Cutaneous Lupus Erythematosus (cCLE) with Emphasis on Differential Diagnosis.
Diagnostics (Basel)
April 2024
Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.
Tumid lupus erythematosus (TLE) has been the subject of heated debate regarding its correct nosographic classification. The definition of TLE has changed over time, varying according to the different studies performed. In this review, we address the initial definition of TLE, the changes that have taken place in the understanding of TLE, and its placement within the classification of cutaneous lupus erythematosus (CLE), with a focus on clinical, histopathological, immunophenotypical, and differential diagnosis aspects.
View Article and Find Full Text PDFTumid lupus masquerading as rosacea.
J Osteopath Med
June 2024
Sun State Dermatology, Orlando, FL, USA.
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.
Lupus Sci Med
December 2023
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Article Synopsis
- The study evaluated the effectiveness of anifrolumab, a monoclonal antibody, on patients with refractory cutaneous lupus erythematosus (CLE) and other skin issues related to systemic lupus erythematosus (SLE).
- Four SLE patients received anifrolumab as an additional treatment, and their symptoms were tracked using the CLASI-A index before and after treatment.
- Results showed significant improvements in skin conditions, including a sharp decrease in CLASI-A scores and better management of symptoms, indicating that anifrolumab is a promising treatment option for resistant cases of CLE in SLE patients, though more research is required.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!